<DOC>
	<DOCNO>NCT00060476</DOCNO>
	<brief_summary>To determine efficacy safety investigational compound ( MK0966 ) prevention prostate cancer .</brief_summary>
	<brief_title>Treatment With MK0966 Prevention Prostate Cancer ( 0966-201 )</brief_title>
	<detailed_description>The duration treatment 6 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<criteria>Regular PSA testing study biopsy require .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>